SynthesisAnnals of global health2023
Asbestos Consumption and Malignant Mesothelioma Mortality Trends in the Major User Countries.
Synthesis in Annals of global health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Comparative Gene Expression Analysis of Epithelioid Pleural and Peritoneal Mesothelioma.Cancers · 2026Article
- Retrospective cohort study on prognostic factors of malignant pleural effusion secondary to pleural mesothelioma.Journal of thoracic disease · 2026Article
- Peritoneal mesothelioma and asbestos exposure: a population-based case-control study in Italy, 2000-2021.Occupational and environmental medicine · 2025Article
- Trends in Pleural Mesothelioma Incidence and Survival in Metropolitan and Nonmetropolitan Areas in the United States.Cancer medicine · 2025Article
- Update on mesothelioma incidence and forecast of future cases in Belgium.BMC public health · 2025Article
- The psychological impact of asbestos exposure: risk perception and emotional distress among former workers in Tuscany.BMC public health · 2025Article
- Inclusion of anti-vascular therapy as a promising option for later-line treatment of malignant pleural mesothelioma: a retrospective study.Journal of thoracic disease · 2025Article
- Mortality from Pleural and Lung Cancer in Railway Maintenance Workers.Life (Basel, Switzerland) · 2025Article
- Trends in Mesothelioma Mortality in the United States Between 1999 and 2020.JTO clinical and research reports · 2025Article
- Integrative eQTL and Mendelian randomization analysis reveals key genetic markers in mesothelioma.Respiratory research · 2025Article
- Projecting future mortality risk of pleural mesothelioma in Italy (2020-2034): Bayesian age-period-cohort analysis over 40 years of death registration.Frontiers in public health · 2025Article
- Engaging Social Stakeholders in National Asbestos Research for Public Health: An Italian Experience.Annals of global health · 2025Article
- Extra-pleural pneumonectomy: How I teach it.JTCVS techniques · 2024Article
- Asbestos ban policies and mesothelioma mortality in Greece.BMC public health · 2024Article
- Transfer learning approach in pre-treatment CT images to predict therapeutic response in advanced malignant pleural mesothelioma.Frontiers in oncology · 2024Article
- Confirmatory validation of a brief patient-reported outcome measure assessing psychological distress in caregivers of malignant mesothelioma patients: the Mesothelioma Psychological Distress Tool-Caregivers.Frontiers in psychology · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The causal association between mesothelioma and asbestos exposure is conclusive, and many studies have proved that the trend in asbestos use is a strong predictor of the pattern in mesothelioma cases with an adequate latency time (generally around 30-40 years or more). Recently, a novel approach for predicting malignant pleural mesothelioma, based on asbestos consumption trend and using distributed non-linear models, has been applied. Objectives: The purpose of this study is to analyse trends in asbestos consumption and malignant mesothelioma mortality in the major asbestos-user countries. Furthermore, we applied distributed non-linear models to estimate and compare epidemiological relationships between asbestos consumption and mesothelioma mortality across these countries. Methods: The study involves major asbestos-user countries in which historical asbestos consumption and mesothelioma mortality data are available. Data on asbestos consumption were derived from worldwide asbestos supply and mesothelioma mortality data from World Health Organization (WHO) mortality archives. A quasi-Poisson generalized linear model was used to model past asbestos exposure and male mesothelioma mortality rates in each country. Exposure-response associations have been modelled using distributed lag non-linear models. Findings and conclusions: According to the criteria defined above, we selected 18 countries with raw asbestos cumulative consumptions higher than two million tons in the period 1933-2012. Overall, a clear linear relationship can be observed between total consumption and total deaths for mesothelioma. Country-specific exposure, lag and age-response relationships were identified and common functions extracted by a meta-analysis procedure. Non-linear models appear suitable and flexible tools for investigating the association between mesothelioma mortality and asbestos consumption. There is a need to improve the global epidemiological surveillance of asbestos-related diseases, particularly mesothelioma mortality, and the absence of reliable data for some major asbestos-user countries is a real concern. A reliable assessment of mesothelioma mortality is a fundamental step towards increasing the awareness of related risks and the need of an international ban on asbestos.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.